STAY INFORMED. VISIT NHIA.ORG/COVID19 FOR INFORMATION AND RESOURCES ABOUT CORONAVIRUS DISEASE (COVID-19).

COVID-19 RESOURCE CENTER

 

NHIA has been closely monitoring the COVID-19 situation for the home and specialty infusion industry in the U.S. Our COVID-19 Resource Center is updated continually, as new information and resources become available. NHIA created this resource center to support our members in providing quality clinical care in the home setting during this time.

The virus was first detected in China and has made its way around the globe. COVID-19 is classified as a coronavirus. Coronaviruses are a large family of viruses common in both people and different species of animals. For COVID-19, it appears this outbreak originated from an animal source. The virus spreads easily from person-to-person. For our home infusion and specialty providers, we are in a position to assist in treatment of affected patients in the home and prevent them from seeking care in health care institutions. Please view our resources below to learn more. 

FDA: Remdesivir not authorized for home administration

The FDA updated its frequently asked questions (FAQ) on remdesivir (Veklury®, Gilead) clarifying that the antiviral drug is not FDA-approved or authorized to treat COVID-19 in a home setting. The agency noted that in clinical trials, patients who were ready for hospital discharge before completing their scheduled duration of treatment did not continue treatment upon discharge with very low readmission rates, concluding that, “data does not support a benefit in continuing outpatient treatment with Veklury if a patient is deemed medically ready for hospital discharge.”

NHIA Home and Specialty Infusion Industry Recommendations for
Providing Services During the COVID-19 Outbreak

COVID-19 Patient screening tool

 

 

NHIA Sterile Compounding Guidance for the Home and Specialty Infusion Industry
During the COVID-19 Outbreak

NHIA’s Talk Infusion Webinars

December 1,2020

COVID-19 Therapeutics in the Home Setting

Presenters: Bill Noyes, Ryan Garst

April 29,2020

Legislative Efforts and the Implications of CMS’ Recently Announced Interim Final Rule for Home Infusion Providers

Presenters: Bill Noyes, Shea McCarthy, Connie Sullivan​

April 2,2020

Legislative Efforts and the Implications of CMS’ Recently Announced Interim Final Rule for Home Infusion Providers
Presenters: Bill Noyes, Shea McCarthy, Connie Sulliv

Presenters: Bill Noyes, Shea McCarthy, Connie Sullivan

March 19,2020

COVID-19: What the Home and Specialty Infusion Community Needs to Know

Presenters: Dr. Valerianna Amorosa, Abby Roth, Shea McCarthy, Bill Noyes, Connie Sullivan 

Get the latest COVID-19 news in your inbox

NHIA members - sign up now to receive the latest COVID-19 updates from NHIA, straight into your inbox. We send bi-weekly emails with information you need to know about the pandemic and how it's impacting the home and specialty infusion industry.

Monoclonal Antibody Resources for COVID-19

Other resources

NHIA


CMS


DME MAC and other Medicare Contractors


Other

We Need Your Support

NHIA is dedicating extra resources to pursue legislation to allow home infusion providers to serve Medicare beneficiaries during the public health emergency related to COVID-19.